Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer by Sestak, I et al.
1 
 
Cross Stratification and Differential Risk by Breast Cancer Index and 1 
Recurrence Score in women with hormone receptor positive lymph-node 2 
negative early stage breast cancer 3 
 4 
Ivana Sestak1, Yi Zhang2, Brock Schroeder2, Catherine A. Schnabel2, Mitch 5 
Dowsett3, Jack Cuzick1, Dennis Sgroi4 6 
 7 
 8 
1 Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen 9 
Mary University London, London, UK 10 
2 bioTheranostics, San Diego, USA 11 
3 Institute of Cancer Research and Academic Department of Biochemistry, Royal 12 
Marsden Hospital, London, UK 13 
4 Molecular Pathology Unit and Centre for Cancer Research, Massachusetts 14 
General Hospital, Boston, USA 15 
 16 
Running title: Differential Risk for distant recurrence by Breast Cancer Index and 17 
Recurrence Score 18 
 19 
Key words: breast cancer index, oncotype recurrence score, cross-stratification, 20 
distant recurrence risk 21 
 22 
Funding 23 
This work was supported by Cancer Research UK, AstraZeneca, and the National 24 
Institute for Health Research Biomedical Research at the Royal Marsden (London, 25 
UK). 26 
 27 
Correspondence to: 28 
Dr. Ivana Sestak 29 
Centre for Cancer Prevention 30 
Wolfson Institute of Preventive Medicine 31 
Queen Mary University of London 32 
Charterhouse Square 33 
London, EC1M 6BQ 34 
United Kingdom 35 
Tel.: +44(0)2078823588 36 
Email: i.sestak@qmul.ac.uk 37 
 38 
Disclosures 39 
IS has nothing to declare. YZ, BS, and CAS are employees of bioTheranostics. MD 40 
received commercial support from AstraZeneca, speaker’s bureau honoraria from 41 
Ventana, and is consultant for Genoptix. JC received research grants from 42 
AstraZeneca. YZ, CAS, and DS are named inventor on a patent to use the breast 43 
cancer index, HOXB13/IL17BR, and molecular grade index assays to predict breast 44 
cancer outcome. 45 
 46 
Word count: 2201 47 
Number of tables/figures: 4  48 
2 
 
Translational Relevance 49 
This is the first study to examine the ability of the Breast Cancer Index to re-stratify 50 
discrepant risk groups for distant recurrence by the Oncotype Recurrence Score. 51 
The study was conducted in a set of 665 postmenopausal women with lymph node 52 
negative, hormone receptor positive breast cancer treated with either tamoxifen or 53 
anastrozole alone. Our results show that the Breast Cancer Index re-stratifies 54 
women with low or intermediate risk for distant recurrence by the Recurrence Score 55 
into clinically relevant different risk groups with significantly different risk of distant 56 
recurrence at 10 years of follow-up. In contrast, the Recurrence Score did not 57 
significantly re-stratify any patients into different risk categories. Our results showed 58 
that the prognostic value of BCI may have potential clinical impact in terms of 59 
improving individualized risk stratification for patients with lymph-node negative early 60 
stage breast cancer. 61 
 62 




Background: Previous results from the TransATAC study demonstrated that both 65 
the Breast Cancer Index (BCI) and the OncotypeDX Recurrence Score (RS) added 66 
significant prognostic information to clinicopathologic factors over a 10-year period. 67 
Here, we examined cross-stratification between BCI and RS to directly compare their 68 
prognostic accuracy at the individual patient level. 69 
Patients and methods: 665 patients with hormone receptor positive (HR+) and 70 
lymph-node negative disease were included in this retrospective analysis. BCI and 71 
RS risk groups were determined using pre-defined clinical cut-points. Kaplan-Meier 72 
estimates of 10-year risk of distant recurrence (DR) and log-rank tests were used to 73 
examine cross-stratification between BCI and RS. 74 
Results: As previously reported, both RS and BCI were significantly prognostic in 75 
years 0 to 10. BCI provided significant additional prognostic information to the 76 
Clinical Treatment Score (CTS) plus RS (∆LR-χ2=11.09; P<0.001) whereas no 77 
additional prognostic information was provided by RS to CTS plus BCI (∆LR-χ2=2.22; 78 
P=0.1). Re-stratification by BCI of the low and intermediate RS risk groups led to 79 
subgroups with significantly different DR rates (P<0.001 and P=0.003, respectively). 80 
In contrast, re-stratified subgroups created by RS of BCI risk groups did not differ 81 
significantly. 82 
Conclusions: In this retrospective analysis, BCI demonstrated increased prognostic 83 
accuracy versus RS. Notably, BCI identified subsets of RS low and RS intermediate 84 
risk patients with significant and clinically relevant rates of DR. These results indicate 85 
that additional subsets of women with HR+, lymph-node negative breast cancer 86 
identified by BCI may be suitable candidates for adjuvant chemotherapy or extended 87 







Breast cancer is the most common cancer and the second leading cause of cancer-93 
related death in women worldwide (1). As a result of significant advancements in the 94 
molecular characterization of breast cancer etiology, clinical management has 95 
evolved to include a comprehensive assessment of the underlying biology of the 96 
patient’s tumor alongside the clinicopathological paradigm to determine treatment 97 
strategies (2, 3). The ongoing challenge in breast cancer is the effective treatment of 98 
a heterogeneous disease associated with a wide spectrum of morphologic and 99 
molecular subtypes with variable outcomes (3). 100 
Genomic tools and expression-based multi-gene signatures have increased 101 
prognostic information for early stage breast cancer patients beyond traditional 102 
clinicopathological factors (4-6). The 21-gene based Recurrence Score 103 
(OncotypeDX; RS) is a well-established multi-gene assay, which was developed to 104 
assess the risk of distant recurrence in women with hormone receptor positive, node-105 
negative breast cancer treated with tamoxifen (7). The RS classifies women into low 106 
(RS<18), intermediate (RS: 18-30), and high (RS>30) risk groups for distant 107 
recurrence (DR). The RS has been validated and evaluated in a number of clinical 108 
trials, and results confirm the prognostic value of RS beyond that of clinical 109 
parameters for DR in the first five years after diagnosis (7-9). The Breast Cancer 110 
Index (BCI) is a second generation gene expression signature developed from the 111 
combination of two biomarkers: the HOXB13:IL17BR expression ratio (H/I) and the 112 
Molecular Grade Index (MGI) (10). H/I is a biomarker that is associated with tumor 113 
responsiveness to endocrine therapy in breast cancer (10, 11). MGI consists of the 114 
average expression of five cell cycle-associated genes and provides quantitative and 115 
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objective molecular assessment of tumor grade and proliferative status (10, 12). The 116 
linear, but not cubic, BCI score provides an estimate for a patient’s risk for DR and 117 
stratifies patients into different risk groups in the early (year 0-5), late (year 5-10) and 118 
overall (year 0-10) time periods (10, 13). 119 
 120 
In a previous study, the linear BCI score was shown to provide more prognostic 121 
information for distant recurrence than RS (13). However, in women with discrepant 122 
scores their values have not been evaluated to date. Here, we investigate the 123 
comparative prognostic strength, agreement and clinical significance of cross 124 





Study population 128 
The translational Arimidex, Tamoxifen Alone or Combination (TransATAC) study 129 
collected formalin-fixed paraffin embedded (FFPE) blocks from women with hormone 130 
receptor positive breast cancer who did not receive chemotherapy as part of their 131 
initial treatment, and who were randomised to either anastrozole or tamoxifen (14). 132 
For this analysis, only women with lymph node-negative disease and data on both 133 
molecular scores have been included (N=665) with a median follow-up of 10 years. 134 
Analytical methods 135 
Analytical methods for RS and BCI (linear model) have been described in detail 136 
previously (5, 6, 14). In brief, RNA was extracted from formalin-fixed paraffin-137 
embedded primary tumour specimens by Genomic Health and gene expression 138 
analysis for both scores was done by real time RT-PCR blinded to patients clinical 139 
outcomes. Risk stratification with RS and BCI was based on pre-specified cut-off 140 
points for 10-year risk of DR: RS <18: low risk, 18-31: intermediate risk, >31: high 141 
risk, and BCI <5.0825: low risk, 5.0825-6.5025: intermediate risk, >6.5025: high risk. 142 
Statistical analyses 143 
The primary objective of this analysis was to determine the differential risk of DR for 144 
women with discrepant RS and BCI scores. The primary endpoint for the comparison 145 
was time to DR with death before DR being treated as a censoring event. The 146 
association between the risk score/categories and distant recurrence was assessed 147 
using hazard ratios (HR) derived from Cox proportional hazard models with 148 
associated 95% Confidence Intervals (CI). HR for the continuous risk scores were 149 
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computed for a difference between the 25th and 75th percentile of the continuous 150 
scores (interquartile HR). 151 
For multivariate analyses, each score was combined with the Clinical Treatment 152 
Score (CTS, an algorithm combining nodal status, tumor size, grade, age and 153 
treatment) to determine the added prognostic information in that score. Changes in 154 
likelihood ratio values (∆LR-χ2) were used to measure and compare the relative 155 
amount of information of one score compared to the other. P-values were two-sided, 156 
based on normal approximation and all confidence intervals (CI) were at the 95% 157 






665 postmenopausal women with HR+, lymph-node negative disease have been 162 
included in this retrospective analysis. Of these, 72 (10.8%) had a DR before 10 163 
years of follow-up. Detailed baseline characteristics for this study group have been 164 
published previously (13). In brief, median age was 62.4 years (IQR 46.7 to 88.4), 165 
most women had moderately differentiated tumors (51.7%), and tumor size of less or 166 
equal to 2cm (73.1%). 167 
 168 
Table 1 shows Hazard Ratios and prognostic information provided (LR-χ2) by each 169 
score and in addition to the CTS and the other score (∆LR-χ2). There was a 170 
significant effect of adding BCI to CTS plus RS (∆LR-χ2=11.09, P=0.0009) whereas 171 
no additional prognostic information to the CTS plus BCI was added by the RS (∆LR-172 
χ2=2.22, P=0.1). Table 2 shows the cross-stratification by RS and BCI into the 173 
respective risk groups. Overall, BCI classified fewer women into intermediate risk 174 
(25.0% vs. 26.8%) but more patients into high risk than RS (16.4% vs. 14.9%). In 175 
total, 283 (42.6%) women were classified into the low, 49 (7.4%) into the 176 
intermediate, and 55 (8.3%) into high risk groups by both BCI and RS, leading to a 177 
concordance of 58.2% between RS and BCI risk categories (Table 2). Among the 178 
278 (41.8%) discordant cases, 24.4% of BCI low risk patients were re-stratified into 179 
RS-intermediate and 3.1% into RS-high risk groups (Table 2). In contrast, BCI re-180 
classified 21.9% and 5.2% of RS-low risk patients as BCI-intermediate and BCI-high 181 
risk, respectively (Table 2). 182 
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The comparison of prognostic accuracy of RS and BCI was further assessed by 183 
Kaplan-Meier analysis. Figures 1 and 2 show cumulative Kaplan-Meier curves for 184 
10-year DR rates for the cross-classification between RS and BCI risk groups. BCI 185 
re-stratified both RS-low and RS-intermediate patients further into risk subsets with 186 
significantly differential risk of DR (LR-χ2=14.64, P<0.001 and LR-χ2=11.75, 187 
P=0.003, respectively; Figure 1A and 1B). Among the 388 women categorized by RS 188 
as low risk, 20 women were reclassified as being high risk by BCI and had a DR risk 189 
of 23.3% by 10 years, which incurs a 7 times higher risk of distant recurrence 190 
compared with those reclassified as the BCI-low risk group (HR=6.77 (2.12-21.58); 191 
Figure 1A). Those reclassified into the intermediate risk group by BCI had a three 192 
times higher risk of DR than those in the low RS risk group (HR=2.94 (1.16-7.46)) 193 
with a 10-year risk of DR of 12.2% (Figure 1A). Similarly, among the 178 women 194 
classified by RS as intermediate risk, 95 women were downgraded to low risk by BCI 195 
with a 10-year DR risk of 7.1% in contrast to 34 women who were upgraded to high 196 
risk by BCI with a 10-year DR risk of 27.8% (Figure 1B). Among women classified by 197 
RS as intermediate risk, those classified by BCI as intermediate or high risk group 198 
had a 4 to 5 times actual higher risk of distant recurrence by 10 years than those 199 
classified by BCI as low risk (HR=3.80 (1.40-10.27) and HR=4.83 (1.72-13.59), 200 
respectively) (Figure 1B). Among the 99 women categorized by RS as high risk, 12 201 
were reclassified by BCI as low risk with a non-significantly lower risk of DR than 202 
those in the intermediate and higher risk groups, (Figure 1C). However, no 203 
significant reclassification of any of the BCI risk groups by the RS was observed in 204 
terms of 10-year DR risk (Figure 2). 205 





We previously reported (13), that the linear BCI added significant prognostic 209 
information for distant recurrence beyond that of clinical parameters and the 210 
Oncotype Dx RS in HR+, lymph-node negative breast cancer (13). Our results 211 
showed that BCI re-categorized patients within low and intermediate RS risk groups 212 
in a statistically significant manner. In contrast, RS did not significantly re-classify 213 
any of the risk groups identified by BCI.  214 
BCI is a gene expression–based signature that algorithmically integrates the 215 
differential expression of 5 cell cycle related genes (MGI), and the expression ratio of 216 
HOXB13/IL17BR (H/I) (10). BCI has been shown to be a significant prognostic factor 217 
in women with hormonal receptor-positive, lymph-node negative disease for both 218 
early (0-5 years) and late (5-10 years) follow-up periods(10, 13). RS is based on a 219 
21-gene signature that was developed in a tamoxifen-treated, lymph node negative 220 
population, and is in part driven by proliferation genes (7, 15). The RS has shown to 221 
be a strong prognostic marker particularly in the early follow-up period (0-5 years) 222 
(16). Although functionally similar in the ability of the two scores to profile mitogenic 223 
activity, there is no overlap in the gene characteristics between RS and BCI. The 224 
correlation between BCI and RS or CTS was weak (rho=0.49, rho=0.45, 225 
respectively) and therefore the significant additional prognostic information shown in 226 
our analysis by BCI is not accounted for by either clinical parameters or RS. Some 227 
comparative studies have shown that multi-gene signatures provide comparable 228 
prognostic performance despite modest overlap (17, 18). However, these studies 229 
utilized public microarray datasets derived from tumor bank specimens, which may 230 
present selection bias with respect to the intended patient population. Here, we 231 
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assessed the genomic signatures at the individual patient level data with clinical 232 
outcome from the TransATAC study. 233 
Results of this study may have implications for clinical decision making related to 234 
early stage breast cancer and potential disease management. For example, patients 235 
in the RS low risk group are generally considered to have a favorable prognosis with 236 
5 years of endocrine therapy alone and are unlikely to benefit from adjuvant 237 
chemotherapy (7, 8). Recent data from the TAILORx trial has confirmed the excellent 238 
prognosis for patients with the lowest RS scores (0-10) over the first 5 years post-239 
diagnosis (19). However, in the present study, BCI identified approximately 22% of 240 
RS low risk patients as intermediate risk and 5% as high risk. These findings suggest 241 
that a significant proportion of RS low risk patients are at an elevated risk of late 242 
recurrence, and may benefit from extended endocrine therapy. Notably, the H/I 243 
component of the BCI test has been shown to be predictive of benefit from extended 244 
endocrine therapy in the MA.17 trial (11). BCI also re-categorized women who were 245 
classified by RS into the high risk into a low risk group. Although some of these 246 
women had large and poorly differentiated tumors, the low risk of DR overall is an 247 
indication that the benefit of additional endocrine or adjuvant chemotherapy is 248 
uncertain is this group. We have previously published data on cross-classification by 249 
the CTS and PAM50 ROR in the TransATAC study (20) where the ROR categorised 250 
more women into the high risk group than the CTS alone. Both of these findings 251 
suggest the importance of non-clinical tumor characteristics, such as biology of these 252 
tumors, that need to be taken into account when assessing DR risk, specifically after 253 
5 years of endocrine treatment (16). Finally, BCI significantly re-stratified the RS 254 
intermediate risk group, a categorization that presents challenges for clinical 255 
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decision-making, identifying approximately half of these patients as having a low risk 256 
of recurrence and half with an elevated risk of recurrence. Of note, the subset of 257 
patients re-stratified by BCI as intermediate or high risk appeared to have an 258 
elevated risk for both early and late recurrences; in contrast to those categorised to 259 
low risk groups by BCI. While not evaluated in this study, these results suggest a 260 
potential role for both adjuvant chemotherapy and extended endocrine therapy that 261 
should be evaluated in future studies. RS cross stratification of the BCI intermediate 262 
risk group resulted in a trend towards statistical significance, with approximately half 263 
of patients downgraded to RS low risk. 264 
Strengths of this analysis are the large sample size of women with lymph-node 265 
negative disease, with a median follow-up of 10 years. Furthermore, this patient 266 
population comes from a well described clinical trial using both tamoxifen and 267 
anastrozole. Our study has limitations. Only a subset of the patients from the main 268 
ATAC trial were included in this analysis (N=665) of whom 10.8% had a distant 269 
recurrence. Secondly, none of these women received chemotherapy and therefore 270 
our results may not apply to chemotherapy-treated women. Of note, patients with a 271 
high RS would receive adjuvant chemotherapy and therefore have a lower risk of 272 
distant recurrence. Finally, this analysis focused on women with lymph-node 273 
negative disease and therefore our results are not applicable to women with lymph-274 
node positive disease. 275 
In summary, this study confirmed that linear BCI provided statistically significant 276 
prognostic information in addition to traditional clinical factors and RS in women with 277 
HR+, lymph-node negative disease treated with adjuvant endocrine therapy. New 278 
findings from this analyses are that the BCI re-classifies quite a few women into 279 
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different risk categories than RS, and that these reclassifications were associated 280 
with substantial differences in patient outcomes. Therefore, our findings on the 281 
prognostic value of BCI may have potential clinical impact with respect to improving 282 
individualized risk stratification for patients with lymph-node negative early stage 283 
breast cancer. 284 
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Figure legends 358 
Figure 1: Kaplan-Meier analysis for 10-year distant recurrence rates in BCI risk 359 
groups within RS-Low (N=388, Figure 1A), RS-Intermediate (N=178, Figure 1B), and 360 
RS-High (N=99, Figure 1C) risk groups. Distant recurrence differences were 361 
evaluated by log-rank test. 362 
Figure 2: Kaplan-Meier analysis for 10-year distant recurrence rates in RS Risk 363 
Groups within BCI-Low (N=390, Figure 2A), BCI-Intermediate (N=166, Figure 2B), 364 
and BCI-High (N=109, Figure 2C) risk groups. Distant recurrence differences were 365 
evaluated by log-rank test. 366 
  367 
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Table 1: Hazard ratio and likelihood ratio tests for BCI and RS (LR-χ2) in the 368 
unvariate analysis and for both scores when added to the CTS and other score 369 
(∆LR-χ2) in the multivariable analysis. 370 
 371 
 372 
 HR (95% CI) LR-χ2  
(P-value) 
RS 1.64 (1.39-1.94) 25.16 
(<0.0001) 
BCI 3.24 (2.31-4.54) 48.96 
(<0.0001) 
  ∆LR-χ2  
(P-value) 
CTS+RS+BCI 2.00 (1.32-3.05) 11.09 
(0.0009) 
CTS+BCI+RS 1.20 (0.95-1.50) 2.22 
(0.1) 
RS=Oncotype DX Recurrence Score; BCI=Breast Cancer Index, CTS=Clinical Treatment Score; HR=Hazard Ratio; 373 
LR=Likelihood Ratio 374 
  375 
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Table 2: Cross-stratification of women into respective risk groups by RS and BCI. 376 
(Grey shaded area=reclassified into higher risk groups by BCI, blue shaded 377 
areas=reclassified into lower risk groups by BCI) 378 
 RS 
BCI Low Intermediate High Total 
Low 283 95 12 390 
Intermediate 85 49 32 166 
High  20 34 55 109 
Total  388 178 99 665 
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